About Us
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, a broad clinical and pre-clinical product pipeline and three proprietary next generation antibody technologies.
About UsCompany overview
Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab’s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab employs approximately 478 people at its core facilities in Denmark, the Netherlands and the United States. In addition Genmab has a regional office in Japan.
2 marketed products
DARZALEX® (daratumumab)
Arzerra® (ofatumumab)
4 proprietary clinical programs
Tisotumab vedotin
Enapotamab vedotin
HexaBody-DR5/DR5
DuoBody-CD3xCD20
4 proprietary technologies
DuoBody® platform
HexaBody® technology
DuoHexaBody® platform
HexElect® platform
About Us/company-overview
